Vaccinex-Privately held now-IMO looking to go public Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vaccinex-Privately held now-IMO looking to go public

VCNX 0.630

-8.7%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: richardred	9/17/2020 10:46:32 AM
	of 17

Vaccinex In Clinical Collaboration Deal With Merck To Evaluate Pepinemab And KEYTRUDA RTTNews Sep. 17, 2020, 02:28 PM (RTTNews) - Biotechnology company Vaccinex, Inc. (VCNX) announced Thursday that it has entered into a clinical collaboration agreement with Merck & Co. (MRK) (known as MSD outside the US and Canada), through a subsidiary, to evaluate the combination of Vaccinex's investigational SEMA4D inhibitor, pepinemab, and Merck's anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in the treatment of patients with advanced, recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). The planned clinical collaboration with pepinemab and pembrolizumab will consist of a dose escalation phase followed by an expansion phase that will enroll up to 65 HNSCC patients allocated to different levels of combined positive score (CPS) of PD-L1 expression. CPS is a biomarker associated with benefit in response to immunotherapy, and a major goal of this study is to determine whether combination therapy can improve response in these populations. Key endpoints of the study include objective response, progression free survival and overall survival.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next